nk520
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2024 (NCT06541405)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06541405 | Early Phase 1 (Phase 1) | Jul 1, 2024 | Base Therapeutics (Shanghai) Co., Ltd., Jiao Tong University |
| NCT06541444 | Early Phase 1 (Phase 1) | Jul 1, 2024 | Base Therapeutics (Shanghai) Co., Ltd., Ningxia Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Base Therapeutics (Shanghai) Co., Ltd. | For profit | 2 | 2 | 1 | 2024 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Ningxia Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1